These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

889 related items for PubMed ID: 31446994

  • 1. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G.
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [Abstract] [Full Text] [Related]

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y, Chen W, Dong L, Duan L, Gao P.
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
    Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS, KEYNOTE-859 investigators.
    Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
    [Abstract] [Full Text] [Related]

  • 5. Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: A meta-analysis of randomized clinical trials.
    Yue Y, Wang Q, Wei M, Ding F, Li J, Zheng B.
    Medicine (Baltimore); 2024 Dec 13; 103(50):e40826. PubMed ID: 39686474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
    Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D.
    JAMA Oncol; 2024 Feb 01; 10(2):185-192. PubMed ID: 38095881
    [Abstract] [Full Text] [Related]

  • 8. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
    Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM.
    JTO Clin Res Rep; 2024 Sep 01; 5(9):100675. PubMed ID: 39399157
    [Abstract] [Full Text] [Related]

  • 9. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N.
    Clin Cancer Res; 2024 Dec 02; 30(23):5353-5364. PubMed ID: 39475359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K.
    Invest New Drugs; 2024 Oct 02; 42(5):538-546. PubMed ID: 39168900
    [Abstract] [Full Text] [Related]

  • 13. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D.
    Lung Cancer; 2024 Dec 02; 198():107999. PubMed ID: 39500124
    [Abstract] [Full Text] [Related]

  • 14. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH.
    Cochrane Database Syst Rev; 2015 Oct 26; 2015(10):CD007698. PubMed ID: 26497719
    [Abstract] [Full Text] [Related]

  • 15. Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
    Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V.
    Am J Clin Dermatol; 2024 Nov 26; 25(6):987-996. PubMed ID: 39377880
    [Abstract] [Full Text] [Related]

  • 16. Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.
    Trestini I, Belluomini L, Dodi A, Sposito M, Caldart A, Kadrija D, Pasqualin L, Riva ST, Scaglione IM, Tregnago D, Avancini A, Insolda J, Confortini L, Casali M, Menis J, Vita E, Cintoni M, Todesco M, Milanese G, Sperduti I, D'Onofrio M, Infante M, Tiseo M, Mele MC, Tortora G, Milella M, Bria E, Pilotto S.
    J Cachexia Sarcopenia Muscle; 2024 Dec 26; 15(6):2349-2360. PubMed ID: 39439222
    [Abstract] [Full Text] [Related]

  • 17. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
    Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C.
    Ann Oncol; 2024 Dec 26; 35(12):1191-1199. PubMed ID: 39306585
    [Abstract] [Full Text] [Related]

  • 18. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.
    Cochrane Database Syst Rev; 2018 Nov 22; 11(11):CD008218. PubMed ID: 30480778
    [Abstract] [Full Text] [Related]

  • 19. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators.
    Lancet Respir Med; 2024 Oct 29. PubMed ID: 39486424
    [Abstract] [Full Text] [Related]

  • 20. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Pérol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S.
    J Clin Oncol; 2024 Dec 29; 42(34):4029-4039. PubMed ID: 39173098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.